HFS
CORT icon

Hantz Financial Services’s Corcept Therapeutics CORT Stock Holding History

Hantz Financial Services’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Buy
3,024
+340
+13% +$20.5K ﹤0.01% 995
2026
Q1 		$108K Buy
2,684
+1,699
+172% +$63.5K ﹤0.01% 1259
2025
Q4 		$34K Buy
985
+524
+114% +$41.2K ﹤0.01% 1578
2025
Q3 		$38K Buy
461
+395
+598% +$28.6K ﹤0.01% 1330
2025
Q2 		$5K Buy
66
+48
+267% +$3.48K ﹤0.01% 1733
2025
Q1 		$2K Buy
+18
New +$1.1K ﹤0.01% 1352

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hantz Financial Services's CORT Position: Q2 2026 in Review

Hantz Financial Services increased its Corcept Therapeutics (CORT) stake by 13% in Q2 2026, buying an estimated $20.5K and bringing the position to 3,024 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #995.

Hantz Financial Services first reported a position in CORT in Q1 2025 and has held it in 6 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Hantz Financial Services held 3,024 shares of Corcept Therapeutics worth $263K as of Q2 2026.
  • Hantz Financial Services bought 340 Corcept Therapeutics shares in Q2 2026, an estimated $20.5K.
  • Corcept Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #995 holding.
  • Hantz Financial Services first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.